Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. trimmed its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 21.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 615,131 shares of the company's stock after selling 172,405 shares during the period. D. E. Shaw & Co. Inc. owned approximately 1.37% of Y-mAbs Therapeutics worth $4,816,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in YMAB. JPMorgan Chase & Co. lifted its stake in Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock worth $399,000 after purchasing an additional 2,854 shares in the last quarter. SG Americas Securities LLC lifted its stake in Y-mAbs Therapeutics by 30.7% during the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after purchasing an additional 4,163 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Y-mAbs Therapeutics by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after purchasing an additional 1,903 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Y-mAbs Therapeutics by 1.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company's stock worth $2,228,000 after purchasing an additional 4,963 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in Y-mAbs Therapeutics by 6,911.6% during the fourth quarter. AlphaQuest LLC now owns 27,135 shares of the company's stock worth $212,000 after purchasing an additional 26,748 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 22.50% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on YMAB. HC Wainwright decreased their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Monday. Truist Financial cut their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Morgan Stanley cut their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. Finally, Oppenheimer cut their price objective on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $16.60.

Y-mAbs Therapeutics Trading Up 4.6%

NASDAQ:YMAB traded up $0.19 during trading hours on Friday, hitting $4.32. The company's stock had a trading volume of 324,293 shares, compared to its average volume of 311,779. The stock has a market capitalization of $195.63 million, a P/E ratio of -8.00 and a beta of 0.53. The stock has a fifty day moving average of $4.41 and a 200-day moving average of $6.74. Y-mAbs Therapeutics, Inc. has a 52-week low of $3.55 and a 52-week high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. On average, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.